Cargando…
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
INTRODUCTION: To evaluate the efficacy and safety of sirukumab in giant cell arteritis (GCA). METHODS: In this multicentre, randomised, double-blind, placebo-controlled, two-part phase 3 trial (NCT02531633; Part A [52-week double-blind treatment]; Part B [104-week follow-up]), patients with GCA were...
Autores principales: | Schmidt, Wolfgang A., Dasgupta, Bhaskar, Luqmani, Raashid, Unizony, Sebastian H., Blockmans, Daniel, Lai, Zhihong, Kurrasch, Regina H., Lazic, Ivana, Brown, Kurt, Rao, Ravi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695797/ https://www.ncbi.nlm.nih.gov/pubmed/32844378 http://dx.doi.org/10.1007/s40744-020-00227-2 |
Ejemplares similares
-
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022) -
Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013) -
Updates on the diagnosis and monitoring of giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2023) -
Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia
por: van der Geest, Kornelis S M, et al.
Publicado: (2020) -
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension
por: Stone, John H, et al.
Publicado: (2021)